Apogee Therapeutics (APGE) Projected to Post Quarterly Earnings on Monday

Key Points

• Apogee Therapeutics is set to announce its Q2 2025 earnings on August 11th, with analysts predicting a loss of ($1.08) per share.
• The company recently reported a higher loss of ($0.95) EPS in its previous quarter, exceeding analysts' expectations of ($1.19) per share.
• Apogee Therapeutics has received multiple analyst upgrades, maintaining a consensus rating of "Buy" with an average price target of $99.00.

Apogee Therapeutics (NASDAQ:APGE - Get Free Report) is projected to announce its Q2 2025 earnings results before the market opens on Monday, August 11th. Analysts expect the company to announce earnings of ($1.08) per share for the quarter.

Apogee Therapeutics (NASDAQ:APGE - Get Free Report) last released its quarterly earnings data on Monday, May 12th. The company reported ($0.95) EPS for the quarter, topping analysts' consensus estimates of ($1.19) by $0.24. On average, analysts expect Apogee Therapeutics to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Apogee Therapeutics Stock Performance

Shares of NASDAQ:APGE traded up $0.26 during midday trading on Monday, reaching $38.01. 21,100 shares of the company's stock were exchanged, compared to its average volume of 756,921. The company's 50 day simple moving average is $40.25 and its two-hundred day simple moving average is $38.08. The firm has a market capitalization of $1.75 billion, a PE ratio of -10.57 and a beta of 1.44. Apogee Therapeutics has a 12 month low of $26.20 and a 12 month high of $63.50.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on APGE. Guggenheim reissued a "buy" rating and set a $116.00 price target on shares of Apogee Therapeutics in a report on Wednesday, July 2nd. BTIG Research boosted their target price on shares of Apogee Therapeutics from $100.00 to $115.00 and gave the stock a "buy" rating in a research note on Monday, July 7th. Wedbush reiterated an "outperform" rating and set a $90.00 price target on shares of Apogee Therapeutics in a research report on Monday, July 7th. Finally, Citigroup reaffirmed a "buy" rating on shares of Apogee Therapeutics in a research note on Monday, July 7th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Apogee Therapeutics currently has a consensus rating of "Buy" and an average price target of $99.00.

Insider Buying and Selling at Apogee Therapeutics

In other news, insider Carl Dambkowski sold 10,090 shares of the company's stock in a transaction that occurred on Wednesday, July 2nd. The shares were sold at an average price of $45.09, for a total value of $454,958.10. Following the completion of the transaction, the insider owned 238,998 shares in the company, valued at $10,776,419.82. This represents a 4.05% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold a total of 15,540 shares of company stock valued at $653,093 in the last ninety days. 42.77% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Apogee Therapeutics stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Apogee Therapeutics Inc. (NASDAQ:APGE - Free Report) by 2.9% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 24,529 shares of the company's stock after purchasing an additional 694 shares during the quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. owned approximately 0.05% of Apogee Therapeutics worth $921,000 as of its most recent SEC filing. Institutional investors and hedge funds own 79.04% of the company's stock.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.